Strategic CDMO Partner ForDoz Pharma specializes in conventional sterile injectables and advanced platforms such as lyophilized formulations, liposomal and nanoparticle delivery, microsphere and polymer-based systems, and in situ depot long-acting injectables, making them a compelling manufacturing partner for complex injectable programs seeking end-to-end CDMO support in the U.S.

U.S. Capacity Gap The company emphasizes expanding U.S. conventional and complex sterile drug expertise and capacity, signaling an opportunity to engage in collaborations that relieve domestic supply constraints for complex injectables and accelerate Phase 2/3 manufacturing scale-up.

Strategic Partnerships Past collaborations with Lupin Pharmaceuticals and LipoMedix highlight a track record of co-development and manufacturing agreements for complex injectables, suggesting a strong entry path for BD discussions with other global or specialty pharma players.

Commercialization Opportunities Their experience with dual development and distribution arrangements indicates potential to partner on both manufacturing and in-market supply of high-value complex injectables in the U.S. and its territories, addressing both supply certainty and regulatory readiness.

Financial Footprint With estimated revenue in the mid-range of private pharma CDMOs, ForDoz presents a scalable platform for growth-centered deals, including toll manufacturing, risk-sharing programs, and capacity-backed commitments to meet rising demand for specialized sterile products.